© 2020 MJH Life Sciences and Dermatology Times. All rights reserved.
Author | John Jesitus
Articles
Bimekizumab phase 3 data reflect rapid, durable response
June 29, 2020
Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.
More treatment options emerging for acne, rosacea
June 17, 2020
In the last three to five years, there has been a tremendous increase in interest in prescription treatments for acne and rosacea, resulting in many promising products entering the marketplace for these conditions.
Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies
April 24, 2020
The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.
Biologic guidelines for psoriasis let providers choose
April 24, 2020
When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.